Roche Broadens Cervical Cancer Testing Lineup With MTM Acquisition
This article was originally published in The Gray Sheet
Roche will seek PMA approval for MTM Laboratories’ cervical cancer tests following acquisition of the diagnostics firm for up to $270 million in a deal announced July 19.
You may also be interested in...
In the midst of a busy January – in which Ventana has signed four publicly disclosed deals to develop companion diagnostics with pharma partners – Ventana President Mara Aspinall talked with “The Pink Sheet” DAILY about pharma’s evolving attitude on personalized medicine, sharing value for joint projects and how Ventana is positioning itself to be the partner of choice for pharma.
Medical device companies raised a total of $906 million in Q3, while in vitro diagnostic/research developers took in $72 million. The top M&As in each segment were private buyouts of public companies: Kinetic Concepts for $6.3 billion and Immucor for $1.9 billion.
Roche has been hiring additional sales reps and training its existing sales force in preparation for the U.S. launch of its cobas HPV test to identify women at high risk of developing cervical cancer.